Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials

Ji, Hong-Long1,2; Liu, Cong3; Zhao, Run-Zhen1

2020-06-26

10.4252/wjsc.v12.i6.471

World Journal of Stem Cells   影响因子和分区

1948-0210

Respiratory diseases, including coronavirus disease 2019 and chronic obstructive pulmonary disease (COPD), are leading causes of global fatality. There are no effective and curative treatments, but supportive care only. Cell therapy is a promising therapeutic strategy for refractory and unmanageable pulmonary illnesses, as proved by accumulating preclinical studies. Stem cells consist of totipotent, pluripotent, multipotent, and unipotent cells with the potential to differentiate into cell types requested for repair. Mesenchymal stromal cells, endothelial progenitor cells, peripheral blood stem cells, and lung progenitor cells have been applied to clinical trials. To date, the safety and feasibility of stem cell and extracellular vesicles administration have been confirmed by numerous phase I/II trials in patients with COPD, acute respiratory distress syndrome, bronchial dysplasia, idiopathic pulmonary fibrosis, pulmonary artery hypertension, and silicosis. Five routes and a series of doses have been tested for tolerance and advantages of different regimes. In this review, we systematically summarize the global trends for the cell therapy of common airway and lung diseases registered for clinical trials. The future directions for both new clinical trials and preclinical studies are discussed.

Pulmonary diseases PULMONARY ARTERIAL-HYPERTENSION COVID-19 MESENCHYMAL STROMAL CELLS Cell therapy ENDOTHELIAL PROGENITOR CELLS Exosomes BONE-MARROW Clinical trial PHASE-I BRONCHOPULMONARY DYSPLASIA TRANSPLANTATION DELIVERY SAFETY MECHANISMS

SCI

英语

其他

Cell Biology

Cell & Tissue Engineering ; Cell Biology

WOS:000554330800006

BAISHIDENG PUBLISHING GROUP INC

1.Univ Texas Tyler, Hlth Sci Ctr Tyler, Dept Cellular & Mol Biol, Tyler, TX 75708 USA;
2.Univ Texas Tyler, Hlth Sci Ctr Tyler, Texas Lung Injury Inst, Tyler, TX 75708 USA;
3.Southern Univ Sci & Technol, Sch Med, Shenzhen 518000, Guangdong, Peoples R China

Ji, Hong-Long,Liu, Cong,Zhao, Run-Zhen. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials[J]. World Journal of Stem Cells,2020,12(6):471-480.

Ji, Hong-Long,Liu, Cong,&Zhao, Run-Zhen.(2020).Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials.World Journal of Stem Cells,12(6),471-480.

Ji, Hong-Long,et al."Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials".World Journal of Stem Cells 12.6(2020):471-480.